Skip to main content
Equibles

Stonepine Capital Management, LLC

Position in RARE — Ultragenyx Pharmaceutical Inc.

CIK 1440771 BEND, OR
Back to RARE Full portfolio

Position in RARE

as of Jun 30, 2026 · filed Aug 17, 2026
Position Value
$834,750
+$834,750 QoQ
Shares Held
25,000
Ownership
0.025%
of shares outstanding
% of Portfolio
0.63%
of 13F equity value
Holder Rank
#160
of 311 holders
Holding Since
Sep 2025
3 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in RARE Over Time

Shares Held

Position Value (USD)

Derivatives in RARE

reported options exposure · as of Jun 30, 2026
CallValue
$6,678,000
CallShares
200,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Stonepine Capital Management, LLC holds $108,574,607 across 61 Biotechnology names. RARE ranks #30 (0.8% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VSTM
Verastem, Inc.
 3,349,627 $12,795,575
2 TENX
Tenax Therapeutics, Inc.
 660,000 $9,603,000
3 NKTR
Nektar Therapeutics
 120,654 $8,422,855
4 ADMA
Adma Biologics, Inc.
 740,000 $6,193,800
5 CAMP
Camp4 Therapeutics Corp
 1,389,622 $6,072,648
6 ELOX
Eloxx Pharmaceuticals, Inc.
 397,160 $5,512,580
7 KZIA
Kazia Therapeutics Ltd
 345,179 $4,860,120
8 CRBP
Corbus Pharmaceuticals Holdings, Inc.
 425,000 $3,986,500

All Filings in RARE

Export CSV
4 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $834,750 25,000
2026-06-30 $6,678,000 200,000
2025-12-31 $2,300,000 100,000
2025-09-30 $601,600 20,000